About Mikael Dolsten

Mikael Dolsten is the Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, Inc., where he leads a team of over 8,000 scientists and oversees all global research operations across six therapeutic areas. He brings over twenty-five years of Pharma experience leading teams that have selected more than 150 candidate drugs for the treatment of human disease and advanced about 20 NME candidate drugs towards late-stage development drugs through registration and successful drug approvals . Under Mikael’s leadership, Pfizer has, as of Q3 2016, achieved about 20 approvals of which more than half are New Medical Entities (NME), ranging from therapies for rheumatoid arthritis, stroke prevention and cancer to a pneumococcal vaccine.

Mikael received his medical degree and doctorate from Lund University in Sweden where he was also appointed as Adjunct Professor in Tumor Immunology. He has published some 150 scientific original articles and book reviews. Mikael is an active leader in the scientific community, currently serving as a fellow of the New York Academy of Medicine. Mikael serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council. In addition, Mikael was recently elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences. – and a member of several other healthcare & science organizations.